Payment overview · 2025
General Payments
$341.80
15 reported records · 10 companies
Healthcare provider profile · identity verified
Mohammad Anwarul Haque Emran, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MYRTLE BEACH, SC · NPI 1811932999
Verified facts
What the public records show
CMS Open Payments records show Mohammad Anwarul Haque Emran, MD received $341.80 in general payments during 2025 across 15 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $90.61 | 26.5% | 5 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $76.31 | 22.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.28 | 10.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.46 | 7.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.76 | 7.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.39 | 6.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.11 | 5.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.71 | 5.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.56 | 5.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.61 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $341.80 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $90.61 | 5 | 2025 |
Source payment records
|
|||||
| Enseal Normalized: enseal |
Device | Ethicon US, LLC | $76.31 | 1 | 2025 |
Source payment records
|
|||||
| Harmonic Normalized: harmonic |
Device | Ethicon US, LLC | $76.31 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.28 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $25.46 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 129 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 106 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 117 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 117 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
117 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
106 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
129 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
117 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 772 | 233 |
| Losartan Potassium | Losartan Potassium | 485 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 465 | 133 |
| Metoprolol Succinate | Metoprolol Succinate | 347 | 114 |
| Omeprazole | Omeprazole | 347 | 108 |
| Lisinopril | Lisinopril | 342 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 339 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 335 | 117 |
| Metformin Hcl | Metformin Hcl | 302 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 233 | 81 |
| Simvastatin | Simvastatin | 217 | 61 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 211 | 150 |
| Alprazolam | Alprazolam | 197 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 70 |
| Pravastatin Sodium | Pravastatin Sodium | 186 | 56 |
| Trazodone Hcl | Trazodone Hcl | 178 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 177 | 61 |
| Glimepiride | Glimepiride | 172 | 58 |
| Prednisone | Prednisone | 172 | 95 |
| Furosemide | Furosemide | 171 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 58 |
| Sertraline Hcl | Sertraline Hcl | 161 | 51 |
| Gabapentin | Gabapentin | 156 | 58 |
| Allopurinol | Allopurinol | 148 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 138 | 43 |
| Ezetimibe | Ezetimibe | 134 | 44 |
| Eliquis | Apixaban | 129 | 41 |
| Potassium Chloride | Potassium Chloride | 119 | 51 |
| Jardiance | Empagliflozin | 117 | 33 |
| Synthroid | Levothyroxine Sodium | 117 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 41 |
| Farxiga | Dapagliflozin Propanediol | 106 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 41 |
| Ozempic | Semaglutide | 101 | 32 |
| Meloxicam | Meloxicam | 94 | 41 |
| Carvedilol | Carvedilol | 89 | 32 |
| Fenofibrate | Fenofibrate Nanocrystallized | 84 | 27 |
| Valsartan | Valsartan | 84 | 31 |
| Montelukast Sodium | Montelukast Sodium | 83 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 18 |
| Alendronate Sodium | Alendronate Sodium | 67 | 22 |
| Celecoxib | Celecoxib | 67 | 21 |
| Xarelto | Rivaroxaban | 65 | 17 |
| Finasteride | Finasteride | 63 | 19 |
| Lorazepam | Lorazepam | 63 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 27 |
| Azithromycin | Azithromycin | 59 | 49 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 58 | 33 |
| Famotidine | Famotidine | 58 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 16 |
| Atenolol | Atenolol | 56 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 16 |
| Bupropion Xl | Bupropion Hcl | 54 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 19 |
| Cephalexin | Cephalexin | 53 | 36 |
| Tramadol Hcl | Tramadol Hcl | 53 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 41 |
| Glipizide | Glipizide | 44 | 15 |
| Spironolactone | Spironolactone | 44 | 15 |
| Temazepam | Temazepam | 44 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 40 |
| Fenofibrate | Fenofibrate | 41 | 13 |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Amoxicillin | Amoxicillin | 40 | 32 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Ramipril | Ramipril | 39 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 21 |
| Warfarin Sodium | Warfarin Sodium | 34 | 12 |
| Clonazepam | Clonazepam | 33 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | 12 |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 24 |
| Fluconazole | Fluconazole | 31 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | 11 |
| Metformin Hcl Er | Metformin Hcl | 31 | 12 |
| Mirtazapine | Mirtazapine | 31 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 27 |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 20 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 18 |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 20 |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | 11 |
| Estradiol | Estradiol | 17 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Sucralfate | Sucralfate | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $341.80 · 15 records | Bayer Healthcare Pharmaceuticals Inc. | Dexcom G6 Transmitter, ELIQUIS, Enseal, FARXIGA, GVOKE HYPOPEN, Harmonic, JARDIANCE, Kerendia, OTEZLA, REPATHA, SYNTHROID, TRELEGY ELLIPTA, UBRELVY | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error